SEC Company Response from GLOBAL MED TECHNOLOGIES INC (CIK 0001009463) — Jul 28, 2005
GLOBAL MED TECHNOLOGIES INC (CIK 0001009463)
Date: July 28, 2005 · CIK: 0001009463 · Accession: 0001021890-05-000114
AI Filing Summary & Sentiment
Referenced dates: July 12, 2005, July 26, 2005
Letter
Staff Accountant Division of Corporate Finance Telephone Number: (202) 551-3468 Facsimile Number: (202) 772-9209 Re: Global Med Technologies, Inc. Letter dated July 12, 2005
Dear Mr. Lee:
The following comments are hereby added to Global Med Technologies, Inc. (“Global Med” or the “Company”) letter dated July 26, 2005 that address comments from the Securities Exchange Commission (“SEC”) from your letter dated July 12, 2005.
In connection with this letter and the letter dated July 26, 2005, the following statements apply:
o
the Company is responsible for the adequacy and accuracy of the disclosure in the filings:
o
staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filings; and
o
the Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Sincerely,
/s/ Michael I. Ruxin
Show Raw Text
CORRESP
1
filename1.htm
Global Med Technologies, Inc.--SEC Response letter addendum
Global
Med Technologies, Inc.
12600 West Colfax
Suite C-240
Lakewood, CO 80215
July 28, 2005
VIA
CORRESPONDENCE
Wilson K. Lee
Staff Accountant
Division of Corporate Finance
Telephone Number: (202) 551-3468
Facsimile Number: (202) 772-9209
Re:
Global
Med Technologies, Inc.
Letter dated July 12, 2005
Dear Mr. Lee:
The
following comments are hereby added to Global Med Technologies, Inc.
(“Global Med” or the “Company”) letter dated July 26, 2005
that address comments from the Securities Exchange Commission (“SEC”)
from your letter dated July 12, 2005.
In
connection with this letter and the letter dated July 26, 2005, the following
statements apply:
o
the Company is responsible for the adequacy and accuracy of the disclosure in
the filings:
o
staff comments or changes to disclosure in response to staff comments do not
foreclose the Commission from taking any action with respect to the filings; and
o
the Company may not assert staff comments as a defense in any proceeding
initiated by the Commission or any person under the federal securities laws of
the United States.
Sincerely,
/s/ Michael I. Ruxin
Michael I.
Ruxin
Chairman of the Board and
Chief Executive Officer and
Acting Principal Financial
and
Accounting Officer